Bibliography
- Hawkins PT, Anderson KE, Davidson K, Stephens LR. Signalling through class I PI3Ks in mammalian cells. Biochem Soc Trans 2006;34(Pt 5):647-62
- Fung-Leung WP. Phosphoinositide 3-kinase delta (PI3Kdelta) in leukocyte signaling and function. Cell Signal 2011;23(4):603-8
- Robak P, Robak T. A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia. Curr Med Chem 2012;19(31):5294-318
- Marwick JA, Chung KF, Adcock IM. Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease. Ther Adv Respir Dis 2010;4(1):19-34
- Ghigo A, Damilano F, Braccini L, Hirsch E. PI3K inhibition in inflammation: toward tailored therapies for specific diseases. Bioessays 2010;32(3):185-96
- Norman P. Selective PI3Kdelta inhibitors, a review of the patent literature. Expert Opin Ther Patent 2011;21(11):1773-90
- Gilead, Inc., Gilead Submits New Drug Application to U.S. FDA for Idelalisib for the Treatment of Indolent Non-Hodgkin's Lymphoma. Press release 2013. Available from: http://www.gilead.com/news/press-releases/2013/9/gilead-submits-new-drug-application-to-us-fda-for-idelalisib-for-the-treatment-of-indolent-nonhodgkins-lymphoma#sthash.ja0r4z8C.dpuf
- Macias-Perez IM, Flinn IW. GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2013;8(1):22-7
- Sanchez E, Li M, Wang C, et al. Phosphoinositide 3'-Kinase (PI3K) Delta Inhibitor, GS-9820, Enhances Anti-Tumor Efficacy When Combined with Conventional Chemotherapeutic Agents in Primary Samples and Human Tumor Xenograft Model of Multiple Myeloma [abstract 4017]. 54th ASH Annual Meeting
- Infinity Pharmaceuticals, Investor Presentation, 2013
- Sriskantharajah S, Hamblin N, Worsley S, et al. Targeting phosphoinositide 3-kinase delta for the treatment of respiratory diseases. Ann NY Acad Sci 2013;1280:35-9
- Hamblin N. Discovery of potent and selective PI3K delta inhibitors for the treatment of respiratory indications, MEDI 10. 245th ACS National Meeting; Spring; 2013
- Safina BS, Sweeney ZK, Li J, et al. Identification of GNE-293, a potent and selective PI3Kdelta inhibitor: navigating in vitro genotoxicity while improving potency and selectivity. Bioorg Med Chem Lett 2013;23(17):4953-9
- Carrera D, Sheng P, Safina BS, et al. Development of a scalable strategy for the synthesis of PI3Kdelta inhibitors: selective and efficient functionalization of purine derivatives. Org Process Res Dev 2013;17:138-44
- E.g. Gilead Calistoga LLC. Novel quinoxaline inhibitors of. WO2013052699; 2013
- Gilead Calistoga LLC. Compositions and methods of treating a disease with (S)-4-amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile. WO2013116562; 2013
- Infinity Pharmaceuticals, Inc., Intellikine LLC. Heterocyclic compounds and uses thereof. WO2013032591; 2013